Neuroreport 11, 2885-2888, (2000). Romieu, P., Martin-Fardon, R., & Maurice, T View abstract in PubMed Post navigationPreviousPrevious post:Effects of sigma receptor agonists on the impairment of spontaneous alternation behavior and decrease of cyclic GMP level induced by nitric oxide synthase inhibitors in mice.NextNext post:Animal models of Alzheimer’s disease and evaluation of anti-dementia drugs.Related PostsAnavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s DiseaseJune 8, 2021Anavex Life Sciences Announces Appointment of Ms Jiong Ma, PhD to Board of DirectorsMay 26, 2021Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual SummitMay 7, 2021Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®February 22, 2021
Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s DiseaseJune 8, 2021
Anavex Life Sciences Announces Participation at Precision in Clinical Trials Virtual SummitMay 7, 2021
Anavex Life Sciences Announces Participation at Upcoming Worldwide National Institutes of Health (NIH) Panel at Rare Disease Day®February 22, 2021
